Alpha Tau Medical Ltd. announced the appointment of Peter Melnyk as Chief Commercial Officer. Mr. Melnyk, a member of board of directors of Alpha Tau Medical Ltd., has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina.

Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure for the launch of Novocure's Optune product. Mr. Melnyk was previously Senior Vice President for Sales and Marketing at OSI Pharmaceuticals, where he led the global commercialization efforts for targeted oncology drug Tarceva. Prior to OSI, Mr. Melnyk was executive director of oncology at Pfizer and Pharmacia and a director of oncology at Bristol-Myers Squibb.

Mr. Melnyk also serves on the Cancer Prevention and Early Detection Advisory Workgroup of C-Change. Mr. Melnyk holds a B.Sc. and M.Sc.

from McGill University in Montreal.